Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krka DDLTS:0HLK 87 EV-to-EBITDA is 11.18 as of Sep. 21, 2026, which is 79% above its 10-year median of 6.24. GuruFocus rates LTS:0HLK with a GF Score™ of 87/100 and a GF Value™ of €50.15 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 746 Drug Manufacturers companies, Krka DD ranks better than 53.89% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Krka DD's enterprise value is €7,079 Mil.
Krka DD's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €633 Mil. Therefore, Krka DD's EV-to-EBITDA for today is 11.18.
The historical rank and industry rank for Krka DD's EV-to-EBITDA or its related term are showing as below:
LTS:0HLK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.19 Med: 6.24 Max: 13.89
Current: 11.44
During the past 13 years, the highest EV-to-EBITDA of Krka DD was 13.89. The lowest was 4.19. And the median was 6.24.
LTS:0HLK's EV-to-EBITDA is ranked better than 53.89% of 746
companies
in the Drug Manufacturers industry
Industry Median: 12.395
vs LTS:0HLK: 11.44
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Krka DD's share price for today is €64.80.
Krka DD's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €13.766.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Krka DD's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HLK vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Krka DD's EV-to-EBITDA falls into.
Krka DD's current Enterprise Value is €7,079 Mil.
Krka DD's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €633 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krka DD (LTS:0HLK) has a EV-to-EBITDA of 11.18 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Krka DD. This is 79% above median its historical median of 6.24. Over the past decade, Krka DD's EV-to-EBITDA has ranged from 4.19 to 13.89. According to the industry distribution chart, Krka DD ranks #344 out of 746 companies in the Drug Manufacturers industry, placing it in the top 46.1%.
Is Krka DD's EV-to-EBITDA too high?
Krka DD's current EV-to-EBITDA of 11.18 is 79% above median its 10-year median of 6.24. Over the past 10 years, this metric has ranged from a low of 4.19 to a high of 13.89. The Drug Manufacturers industry median EV-to-EBITDA is 12.40. Krka DD's value of 11.18 is 9.8% below this industry median. Based on the distribution chart, Krka DD ranks #344 out of 746 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Krka DD has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #344 out of 746 companies for EV-to-EBITDA. This puts Krka DD in the upper half of its industry. The industry median EV-to-EBITDA is 12.40. Krka DD's value of 11.18 is 9.8% below this benchmark. Historically, Krka DD's own EV-to-EBITDA has ranged from 4.19 to 13.89 over the past decade. While the company's 10-year median is 6.24 vs. the industry median of 12.40, Krka DD has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.40, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current EV-to-EBITDA of 11.18 is 9.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Krka DD. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current EV-to-EBITDA is 11.18, which is 79% above median its own 10-year median of 6.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (LTS:0HLK) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.15, compared to a current price of €64.80 — trading 29.2% above its estimated fair value. The current EV-to-EBITDA is 11.18, which is 79% above median its 10-year median of 6.24 and 9.8% below the Drug Manufacturers industry median of 12.40. Krka DD's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Krka DD (LTS:0HLK), the current EV-to-EBITDA is 11.18 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (LTS:0HLK) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €64.80 is trading 29.2% above its estimated GF Value™ of €50.15.
GuruFocus considers Krka DD to be Modestly Overvalued.
Key valuation signals for LTS:0HLK:
EV-to-EBITDA: 11.18 (79% above median its 10-year median of 6.24)
GF Value™: €50.15 vs. price of €64.80 (29.2% above fair value)
Industry Position: 9.8% below the Drug Manufacturers median (#344 of 746)
No single metric tells the full story. See the LTS:0HLK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
87GF Score
Get the complete analysis for LTS:0HLK
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HLK has been successfully added to your 
